Tamjeed Ahmed, MD
Hematology & Oncology · Gallatin, TNNPI 1235420316
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,581 of the $11,171 with a category attached, or 67.9%. 56 manufacturers reported payments, led by Partner Therapeutics, Inc. at 33.2% of the total. 2025 is the largest year on record at $6,679, more than ten times the $313 reported in 2019.
Across 341 payments — averaging $32.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Partner Therapeutics, Inc.$4K
- AstraZeneca$567
- Novartis$523
- Merck$491
- Pfizer$419
- Regeneron Healthcare Solutions, Inc.$372
- plus $5K from 50 others
Across 3 payments — averaging $12,923 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$30K
- Merck$9K
What the payments were for
- Consulting fees$2,40021%
- Travel & lodging$1,12510%
- Food & beverage$7,58168%
- Education$661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bizengri$3,465
- ONIVYDE$153
- SOMATULINE DEPOT$153
How this compares
$11,171 in reported general payments places this provider in the 60th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 88 | $1,444,858 |
| IbrancePalbociclib | 36 | $571,413 |
| JakafiRuxolitinib Phosphate | 29 | $508,081 |
| VerzenioAbemaciclib | 25 | $356,900 |
| LonsurfTrifluridine/Tipiracil Hcl | 26 | $220,524 |
| VenclextaVenetoclax | 13 | $203,303 |
| ImbruvicaIbrutinib | 14 | $203,000 |
| CalquenceAcalabrutinib Maleate | 12 | $173,352 |
| Abiraterone Acetate | 12 | $60,129 |
| XareltoRivaroxaban | 16 | $15,684 |
| EliquisApixaban | 23 | $13,289 |
| Imatinib Mesylate | 12 | $12,390 |
| Letrozole | 111 | $3,631 |
| Prochlorperazine Maleate | 100 | $1,226 |
| Dexamethasone | 77 | $1,047 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $258 | $1,444,85888 claims |
| PfizerIbrance, Eliquis | $419 | $584,70359 claims |
| Incyte CorporationJakafi | $32 | $508,08129 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $40 | $357,08349 claims |
| Taiho Oncology, Inc.Lonsurf | $148 | $220,52426 claims |
| AbbVieVenclexta | $295 | $203,30313 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $115 | $203,00014 claims |
| AstraZenecaCalquence | $567 | $173,35212 claims |
| Johnson & JohnsonXarelto | $342 | $15,68416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Gallatin
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Jason PorterGermantown$756K
- Brian RiniNashville$601K
- Wade IamsNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.